These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22313910)

  • 1. Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2011; 59(6):410-3. PubMed ID: 22313910
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
    Sivolella S; Lumachi F; Stellini E; Favero L
    Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the jaw and bevacizumab therapy.
    Van Poznak C
    Breast Cancer Res Treat; 2010 Jul; 122(1):189-91. PubMed ID: 20464477
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab, sunitinib: osteonecrosis of the jaw.
    Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682016
    [No Abstract]   [Full Text] [Related]  

  • 7. Avascular osteonecrosis of the jaw as a side effect of bisphosphonate treatment.
    Bamias A; Terpos E; Dimopoulos MA
    Onkologie; 2010; 33(6):288-9. PubMed ID: 20523090
    [No Abstract]   [Full Text] [Related]  

  • 8. Osteonecrosis after administration of intravitreous bevacizumab.
    Hopp RN; Pucci J; Santos-Silva AR; Jorge J
    J Oral Maxillofac Surg; 2012 Mar; 70(3):632-5. PubMed ID: 21757280
    [No Abstract]   [Full Text] [Related]  

  • 9. Osteonecrosis of the mandible associated with bevacizumab therapy.
    Santos-Silva AR; Belizário Rosa GA; Castro Júnior Gd; Dias RB; Prado Ribeiro AC; Brandão TB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Jun; 115(6):e32-6. PubMed ID: 23567260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
    Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
    Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab.
    Katsenos S; Christophylakis C; Psathakis K
    Arch Bronconeumol; 2012 Jun; 48(6):218-9. PubMed ID: 22429334
    [No Abstract]   [Full Text] [Related]  

  • 12. The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw.
    Fantasia JE
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):547-53. PubMed ID: 26515736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit.
    Dişel U; Beşen AA; Özyılkan Ö; Er E; Canpolat T
    Oral Oncol; 2012 Feb; 48(2):e2-3. PubMed ID: 21865077
    [No Abstract]   [Full Text] [Related]  

  • 14. Aflibercept: osteonecrosis of the jaw: Watch out for high-risk situations.
    Prescrire Int; 2016 Nov; 25(176):271. PubMed ID: 30730125
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw.
    Ruggiero SL
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):479-87. PubMed ID: 26293329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of the jaw related to bevacizumab.
    Estilo CL; Fornier M; Farooki A; Carlson D; Bohle G; Huryn JM
    J Clin Oncol; 2008 Aug; 26(24):4037-8. PubMed ID: 18711196
    [No Abstract]   [Full Text] [Related]  

  • 17. New oncology drugs and osteonecrosis of the jaw (ONJ).
    Migliorati CA; Covington JS
    J Tenn Dent Assoc; 2009; 89(4):36-8; quiz 38-9. PubMed ID: 20102031
    [No Abstract]   [Full Text] [Related]  

  • 18. Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association?
    Aragon-Ching JB; Dahut WL
    Oncologist; 2008 Dec; 13(12):1314; author reply 1315. PubMed ID: 19088325
    [No Abstract]   [Full Text] [Related]  

  • 19. [Not Available].
    Ruhin B
    Rev Stomatol Chir Maxillofac Chir Orale; 2016 Nov; 117(5):363-365. PubMed ID: 27364432
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines.
    Patel S; Choyee S; Uyanne J; Nguyen AL; Lee P; Sedghizadeh PP; Kumar SK; Lytle J; Shi S; Le AD
    Oral Dis; 2012 Oct; 18(7):625-32. PubMed ID: 22420684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.